A significant reduction in the tumor volume and weight was observed in the MTCH1 deficiency or Sorafenib-treated group compared with the control group (Fig. 6D–F), suggesting a role for MTCH1 in cervical cancer growth. Here, MTCH1 is linked to neoplasm.